Is my vaccination programme working? Vaccine effectiveness: measuring vaccine protection in the field

Similar documents
FMD VACCINES AND THEIR USE IN VACCINATION PROGRAMMES: THEORY AND PRACTICE

Post-Vaccination Monitoring

Role of vaccination and the evaluation of LSD control programmes

FMD vaccination and postvaccination. guidelines. Samia Metwally (FAO) Animal Production and Health Division FAO of the United Nations Rome, Italy

Mass vaccination, immunity and coverage: Modelling population protection against FMD in Turkish cattle. Theo Knight-Jones Epidemiologist, ILRI

Open to: Model developers and users with an interest in the objective

FMD VACCINE AND VACCINATION. Ahmad Al-Majali Dean, Faculty of Vet Medicine JUST Jordan

The global control of FMD; challenges and opportunities

West Eurasia Regional Roadmap Meeting Country Presentation 2012

Cedivac-FMD; Duration of Immunity in cattle, sheep and pigs. 2004, 8203 AA Lelystad, The Netherlands * Corresponding Author

FMD in Libya. Dr. Abdunaser Dayhum National Center of Animal Health Libya

Elements of FMD post-vaccination monitoring programme / Éléments du programme de surveillance post-vaccination contre la fièvre aphteuse

Questionnaire results

FMD Control in Dairy Colonies Milk Production System in Pakistan

Requirements of the Terrestrial Code for FMD surveillance. Dr David Paton Dr Gideon Brückner

Progressive Control of Foot and Mouth Disease in PAKISTAN

FMD CONTROL IN KYRGYZSTAN State Inspectorate for Veterinary and Phyto- Sanitary Security under the Government of the Kyrgyz Republic

WEST EURASIA FMD LAB PHASE ACTIVITY PROPOSAL. A. Naci BULUT Head of the Diagnosis Department, Şap Institute

Importance of Vaccines for Managing FMD

Why to vaccinate? Lumpy skin disease prevention, control, and awareness workshop Budapest, Hungary, 7-9 March 2017

REPORT ON THE SITUATION OF FMD IN TURKEY

FMD - TURKEY. Yener ŞEKERCAN. Veterinary Officer General Directorate of Food and Control Ankara/TURKEY

Pillar 2: Reduce Risk to members from the FMD Situation in the European Neighbourhood Accomplishments and Lessons Learned

Republic of Kazakhstan

EPIDEMIOLOGICAL SITUATION. for S&GP, PPR andbt

Regulation of FMD vaccines within the European Union

Foot and mouth disease control strategies in North Africa and the Middle East the current

Foot and mouth disease vaccination and post-vaccination monitoring. Guidelines. Editors Samia Metwally Susanne Münstermann

Foot and mouth disease vaccination and post-vaccination monitoring. Guidelines. Editors Samia Metwally Susanne Münstermann

Optimising surveillance systems for early disease detection. Nick Honhold October 2007

Surveillance strategies for Foot and Mouth Disease to prove absence from disease and absence of viral circulation

FMD Report - Syria 6 th Regional FMD West Eurasia Roadmap Meeting - Almaty, Kazakhstan 28 to 30 April 2015

PROGRESS REPORT FOR TURKEY ON FMD SITUATION AND CONTROL MEASURES

PCP Stage 1 focus: To gain an understanding of the epidemiology of FMD in the country and develop a risk-based approach to reduce the impact of FMD

Manufacturers expected contribution to the progressive control of Foot-and-Mouth Disease in South Asia

FOOT AND MOUTH DISEASE SURVEILLANCE IN CENTRAL AND SOUTHERN SOMALIA

ACHIEVEMENT on FMD CONTROL POLICY IN TURKEY

PRAGMATIST: A DECISION SUPPORT TOOL FOR FOOT AND MOUTH DISEASE VACCINE BANK MANAGERS

Progress report on the EUFMD supported actions in FMD Control in the Republic of Azerbaijan. Leos Celeda, Chairman EUFMD

OIE/FAO Global Conference on foot and mouth disease. The way towards global control. Paraguay: 24 to 26 June Draft Resolution version 8

16 th JPC REMESA meeting

Mission of the Community Veterinary Emergency Team to Bulgaria. (16-21 July 2018)

Progressive Control Pathway for Foot and Mouth Disease (PCP-FMD) Checklist Explanation. March 2013

Progressive Control Pathway for Foot and Mouth Disease (PCP-FMD) Checklist Explanation. March 2013

Richard Reeve Boyd Orr Centre for Population and Ecosystem Health University of Glasgow

Manual 3. Foot and Mouth Disease vaccination and post-vaccination monitoring

This CRP is proposed for five years with three RCM. To apply, please see our website for directions:

FMD Control Initiatives in Bangladesh

Foot and Mouth Disease Middle East situation Summary of Answers to the Questionnaire Beirut, Lebanon, 7 9 April 2009

FOOT AND MOUTH DISEASE DIAGNOSTICS: REQUIREMENTS FOR DEMONSTRATION OF FREEDOM FROM INFECTION

Event based and active surveillance for avian influenza

in control group 7, , , ,

Keith Sumption Secretary, European FMD Control Commission (EuFMD) FAO, Rome

Standing Technical Committee Report

Lumpy Skin Disease in Israel Nadav Galon, CVO Israel FAO Webinar

Strengthening FMD prevention and emergency response capacity in the Trans-Caucasian countries (MTF/INT/003/EEC)

7th Regional FMD West Eurasia Roadmap Meeting The incursion of new strain of FMD virus on the territory of Armenia

Epidemiology of measles in infants younger than 6 months: analysis of surveillance data

Vaccination against Lumpy skin disease virus

SEACFMD ACTIVITIES FOCUS ON

SCIENTIFIC DISCUSSION

FAO Collaborative Study Phase XVII: Standardisation of FMD Antibody Detection

National Foot and mouth Disease Control and Eradication Plan in Thailand

Analytic Methods for Infectious Disease Lecture 3

Direct beneficiary Countries: Georgia, Armenia and Azerbaijan Proposed Implementation date: 1/1/06

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Elements of the FMD control problem in Southern Africa: 2

Update to Iowa Foot and Mouth Disease (FMD) and Livestock Emergency Management Plans

Prevalence of Antibodies Against Foot-and-Mouth Disease Virus in Cattle in Kasese and Bushenyi Districts in Uganda

Foot and Mouth Disease vaccination is effective: Quantification of FMD transmission with and without vaccination

FMD Progressive Control Pathway. Peter de Leeuw, DVM, PhD

Regional Status and FMD s Control Strategies in North Africa

Keith Sumption Secretary, European FMD Control Commission (EuFMD) FAO, Rome

Longevity of protection in cattle following vaccination with emergency FMD vaccines from the UK strategic reserve

FMD in Great Britain (Surrey)

2004, OIE initiative Ad hoc Group on Antigen & Vaccine Banks for FMD

Conclusions of the SAGE Working Group on Measles and Rubella June 2017, Geneva

Regional Training Needs

FMD diagnostics: current developments and application in the context of FMD control in endemic countries Wilna Vosloo

MAXIMISING EFFICIENCY WITH A SURVEILLANCE STRATEGY FOR FOOT-AND-MOUTH DISEASE DURING AN OUTBREAK IN A PREVIOUSLY FMD-FREE COUNTRY.

Overview of WRL FMD. Historical perspective. Principal activities. FMD threats. Needs/prospects. David Paton

FINLAND S ANIMAL HEALTH SERVICE (FAHS)

Role of the EuFMD/European countries - West EurAsia and other Regional Roadmaps

Lumpy Skin Disease Contingency Plan Template

A study on the trends of Foot-and-Mouth Disease vaccinations in large ruminants in Cambodia. JEREMY KAN Final Year BVSc

Mission of the Community Veterinary Emergency Team to Greece

Lumpy Skin Disease in Greece Update. Situation as at 7 October 2015)

Findings on FMD in Afghanistan and Pakistan

The Progressive Control Pathway (PCP) for FMD control

Paper on needs and support to be provided to North African countries, members of REMESA regarding the coordinated control of FMD

Unique features of foot and mouth disease in Southern Africa

EPIDEMIOLOGICAL DEVELOPMENTS AND CONTROL OF FOOT AND MOUTH DISEASE IN ASIA

The Global control of FMD - Tools, ideas and ideals Erice, Italy October 2008 THE STATUS OF FOOT-AND-MOUTH DISEASE (FMD) IN ETHIOPIA

CONTROL AND ERADICATION OF LUMPY SKIN DISEASE IN SOUTH-EASTERN EUROPE TECHNICAL ITEM II. by Dr Eeva S.M. Tuppurainen and Dr Nadav Galon

Dr Ghazi Yehia OIE Regional Representative for the Middle East

Best practice guide for the control of bovine respiratory disease

The FAO/OIE FMD Global Control Strategy Joseph Domenech, OIE on behalf of the joint FAO/OIE GF TADs PPR Working Group

REGIONAL REFERENCE LABORATORY FOR FMD IN SOUTH EAST ASIA DEPARTMENT OF LIVESTOCK DEVELOPMENT PAKCHONG, NAKHONRATCHASIMA, THAILAND

e-bug: Vaccinations Teacher Sheet Student worksheet 1 answers

Transcription:

Is my vaccination programme working? Vaccine effectiveness: measuring vaccine protection in the field Theo Knight-Jones FAO-EU-EuFMD webinar for West-Eurasian veterinary services 15 January 2015

Contents of presentation Overview of traditional vaccine protection evaluation methods How to assess vaccine protection during an outbreak Overview of other vaccine effectiveness study designs

Evaluation of FMD vaccines traditionally based on: 1. Challenge studies Control conditions and ensure adequate exposure Small numbers and may not represent natural challenge 2. Serological evaluation Vaccine matching tests Useful but imprecise test Post vaccination SP antibody response peak response and over entire intervaccination interval Useful but what field virus are you concerned about and how does this relate to the test and vaccine antigen Have you correlated your antibody response with protection against the virus of concern in a challenge study

Evaluation of FMD vaccines traditionally based on: 1. Challenge studies Control conditions and ensure adequate exposure Small numbers and may not represent natural challenge 2. Serological evaluation Vaccine matching tests Useful but imprecise test Post vaccination SP antibody response peak response and over entire intervaccination interval Useful but what field virus are you concerned about and how does this relate to the test and vaccine antigen Have you correlated your antibody response with protection against the virus of concern in a challenge study

Evaluation of FMD vaccines traditionally based on: 1. Challenge studies Control conditions and ensure adequate exposure Small numbers and may not represent natural challenge 2. Serological evaluation Vaccine matching tests Useful but imprecise test Post vaccination SP antibody response peak response and over entire intervaccination interval Useful but what field virus are you concerned about and how does this relate to the test and vaccine antigen Have you correlated your antibody response with protection against the virus of concern in a challenge study

Field study Batch variability Cold chain Shelf life Variable animal response Match with field virus Field protection: protection that counts Time since last vaccinated Number of doses in lifetime Level/duration of virus exposure

Vaccine effectiveness The percentage reduction in incidence in vaccinated compared to unvaccinated individuals under field conditions

Vaccine effectiveness The percentage reduction in incidence in vaccinated compared to unvaccinated individuals under field conditions Incidence risk [percentage or proportion affected during defined period] e.g. 0.01 or 1% Incidence rate [number affected/sum of time at risk for all individuals] 0.2 cases/animal year at risk

Concerned about outbreaks in vaccinated population Failure to vaccinate or a vaccine failure?

Concerned about outbreaks in vaccinated population Failure to vaccinate or a vaccine failure? 1. Are vaccinated animals protected from FMD? Vaccine effectiveness 2. Are the animals being vaccinated (adequately)? Vaccine coverage

Concerned about outbreaks in vaccinated population Failure to vaccinate or a vaccine failure? 1. Are vaccinated animals protected from FMD? Vaccine effectiveness 2. Are the animals being vaccinated (adequately)? Vaccine coverage

Concerned about outbreaks in vaccinated population Failure to vaccinate or a vaccine failure? 1. Are vaccinated animals protected from FMD? Vaccine effectiveness 2. Are the animals being vaccinated (adequately)? Vaccine coverage

Vaccine failure or failure to vaccinate What is the bigger problem in your country? Vaccine coverage Vaccine effectiveness Both Don t know

Vaccine effectiveness After an outbreak: Compare incidence in vaccinated and unvaccinated Vaccinated versus Unvaccinated

Vaccine effectiveness After an outbreak: Compare incidence in vaccinated and unvaccinated Vaccinated versus Unvaccinated

Vaccine effectiveness After an outbreak: Compare incidence in vaccinated and unvaccinated VE = 1- Incidence in Vaccinated x 100% Vaccinated Incidence versus in Unvaccinated Unvaccinated or Unvac incidence Vac inc x 100% Unvac inc

Vaccine effectiveness After an outbreak: Vaccine efficacy -> under controlled trial Compare incidence in vaccinated and unvaccinated Vaccine effectiveness - > observational study (field study program conditions) Vaccinated versus Unvaccinated

Vaccine effectiveness After an outbreak: What is VE in this example: Compare incidence Vaccinated incidence vaccinated = 3/10 = and 30% unvaccinated Unvaccinated incidence = 9/10 = 90% VE = 90-30 = 66.6% 90 Vaccinated versus Unvaccinated

Vaccine effectiveness After an outbreak: What is VE in this example: Compare incidence Vaccinated incidence vaccinated = 3/10 = and 30% unvaccinated Unvaccinated incidence = 9/10 = 90% VE = 90-30 = 66.6% 90 Vaccinated versus Unvaccinated

Vaccine effectiveness After an outbreak: What is VE in this example: Compare incidence Vaccinated incidence vaccinated = 3/10 = and 30% unvaccinated Unvaccinated incidence = 9/10 = 90% VE = 90-30 = 66.6% 90 Vaccinated versus Unvaccinated

Vaccine effectiveness After an outbreak: What is VE in this example: Compare incidence Vaccinated incidence vaccinated = 3/10 = and 30% unvaccinated Unvaccinated incidence = 9/10 = 90% VE = 90-30 = 0.666 = 66.6% 90 Vaccinated versus Unvaccinated

Vaccine effectiveness After an outbreak: What is VE in this example: Compare incidence Vaccinated incidence vaccinated = 3/10 = and 30% unvaccinated Unvaccinated incidence = 9/10 = 90% VE = 90-30 = 0.666 = 66.6% 90 or Vaccinated versus Unvaccinated VE = 1-30 = 0.666 = 66.6% 90

Vaccine effectiveness After an outbreak: What is VE in this example: Compare incidence Vaccinated incidence vaccinated = 3/10 = and 30% unvaccinated Unvaccinated incidence = 9/10 = 90% VE = 90-30 = 0.666 = 66.6% 90 or Vaccinated versus Unvaccinated VE = 1-30 = 0.666 = 66.6% 90 VE 100% = complete protection with 0% incidence in vaccinated VE 0% = no protection same incidence in vaccinated & unvaccinated

Question At an outbreak 80% of unvaccinated cattle had clinical FMD 20% of vaccinated cattle had clinical FMD What is vaccine effectiveness? a) 75% b) 60% c) 25% d) 40% VE = Unvac incidence Vac inc x 100% Unvac inc

At an outbreak Question 80% of unvaccinated cattle had clinical FMD 20% of vaccinated cattle had clinical FMD Protection against clinical disease What Protection is against vaccine infection effectiveness? (NSP if purified vaccine!) or infectiousness a) 75% b) 60% c) 25% d) 40% VE = Unvac incidence Vac inc x 100% Unvac inc

Pathogen exposure What if only farmers whose animals have a high risk [of exposure to FMD virus] vaccinate their animals? e.g. dealers, use common grazing??? Will vaccine effectiveness increase or decrease?

Pathogen exposure What if only farmers whose animals have a high risk [of exposure to FMD virus] vaccinate their animals? e.g. dealers, use common grazing??? Will vaccine effectiveness increase or decrease? This bias will decrease VE vaccine may protect but vaccinated animals have a greater virus challenge than unvaccinated unfair comparison

But FMD risk is affected by other factors that affect susceptibility and exposure Age Prior infection Number of times previously vaccinated Level of exposure [common or private grazing] Herd size?

But FMD risk is affected by other factors that affect susceptibility and exposure Age Prior infection Number of times previously vaccinated Level of exposure [common or private grazing] Herd size?

But FMD risk is affected by other factors that affect susceptibility and exposure Age Assess different age groups separately Exclude <7 months maternal immunity Prior infection Exclude village or exclude old cattle if outbreak a few years a go Number of times previously vaccinated Assess separately according to number of doses Limitation - May not be able to adjust for both age & number of doses closely correlated? Level of exposure [common or private grazing] Herd size?

But FMD risk is affected by other factors that affect susceptibility and exposure Age Assess different age groups separately Exclude <7 months maternal immunity Prior infection Exclude village or exclude old cattle if outbreak a few years a go Number of times previously vaccinated Assess separately according to number of doses Limitation - May not be able to adjust for both age & number of doses closely correlated? Level of exposure [common or private grazing] Herd size? Ideally - vaccinated and unvaccinated are similar in terms of confounders in reality differences will exist that must be adjusted for through design and during analysis

Incidence risk by age: Example 1 Age Vaccinated Unvaccinated VE 7-12 months 15% 60% 75% 13-24 months 25% 85% 71% >24 months 5% 25% 80% Overall 20% 80% 75% In this example age makes little difference to VE So report crude VE unadjusted for age (75%)

Incidence risk by age: Example 2 Age Vaccinated Unvaccinated VE 7-12 months 20% 30% 33% 13-24 months 25% 100% 75% >24 months 10% 25% 60% Overall 15% 90% 83% Can still have unacceptable incidence in vaccinated even when good VE

Incidence risk by age: Example 2 More complex analysis sometimes needed Age Vaccinated Unvaccinated VE 7-12 months 20% 30% 33% get weighted average using Mantel-Haenszel methods 13-24 www.winepi.net months 25% Programmed 100% spreadsheet 75% or stats software >24 months 10% 25% 60% regression modelling [adjust for many factors at same time] Overall 15% 90% 83% Remember p values and confidence VE varies intervals! by age Unvaccinated 13-24 Report VE for each age group months probably over-represented in overall sample

Simplest of all What if no unvaccinated animals? Just looking at incidence by number of doses is useful

Farm 1 Vaccine Lyons, Kenya Incidence risk versus Number of lifetime doses Incidence plateau among older animals no vaccine effect! Lower incidence in youngstock maternal protection? 36

Farm 2 Vaccine Lyons, Kenya Incidence risk versus Number of lifetime doses Declining incidence implies some vaccine effectiveness Maternal antibody? Incidence plateau 37

Possible reasons for incidence pattern on Farm 2 40% incidence in multiply vaccinated clearly reveals a problem. Potency? Match? Cold chain? Suboptimal schedules as well? Can have multiple reasons for poor VE! 38

Retrospective effectiveness studies Turkey 2011/12 Four VILLAGE outbreak investigations: Asia-1 1 3 2, 4 Knight-Jones T.J., Bulut A.N., Gubbins S., Stark K.D., Pfeiffer D.U., Sumption K.J., Paton D.J. 2014 Retrospective evaluation of foot-and-mouth disease vaccine effectiveness in Turkey. Vaccine (32), 1848-1855.

Sampling-Retrospective cohort Find outbreak of the right strain where the vaccine has been used Timing: At or near the end of an outbreak Time since vaccination is important [too soon or too long after vaccination]

Sampling-Retrospective cohort 1. Within a village at end of outbreak: 1. Select all or sample of affected households [households with cases or NSP positive - known virus exposure] 2. Random or evenly spaced in village 3. Sample several villages affected by outbreak [need at least 200-400 animals] 4. Need vaccinated and unvaccinated animals for comparison 2. Within a household: 1. Collect details of all cattle >5 months [may exclude more during analysis] 3. For each selected animal 1. Ask owner about vaccination and FMD history cross-ref with written records 2. Examine for clinical signs 3. Assess infection history by serology (<30 months)

Results Vaccine Investigation Unvaccinated Vaccinated Unadjusted Vaccine effectiveness (95% CI) FMD/Total Shamir 1 - Ardahan 19/47 (40%) 188/249 (76%) -87% (-140% to -40%) 2 - Afyon-1 64/127 (50%) 14/91 (15%) 73% (51% to 85%) Sindh08 3 Denizli 55/68 (81%) 134/337 (40%) 51% (41% to 59%) 4 - Afyon-2 71/124 (57%) 69/187 (37%) 36% (18% to 49%) Need to adjust for other confounding factors age, husbandry, etc

Asia-1: Multivariable model Risk factor Vaccine effectiveness [95% CI] Recently Vaccinated Sindh-08 69% [50% to 81%] Shamir -36% [-137% to 22%] Rate Ratio Avoid common grazing 0.2 [0.1-0.36] Age: Every month >15 months 0.98 [0.977-0.99] Herd size >30 0.25 [0.1 0.5] Random intercept: Village/Owner St dev of intercept = 6 / 1.4

Asia-1: Multivariable model Risk factor Vaccine effectiveness [95% CI] Recently Vaccinated Sindh-08 69% [50% to 81%] Shamir -36% [-137% to 22%] 63% [ 29% to 81%] protection against infection Rate Ratio Avoid common grazing 0.2 [0.1-0.36] Age: Every month >15 months 0.98 [0.977-0.99] Herd size >30 0.25 [0.1 0.5] Random intercept: Village/Owner St dev of intercept = 6 / 1.4

Results Several investigations for one vaccine preferable Vaccine But: Incidence in vaccinated alone can be informative Investigation Unvaccinated Vaccinated Unadjusted Vaccine effectiveness FMD/Total r 1 -value (95% < CI) 0.3 Poor vaccine match: Shamir 1 - Ardahan 19/47 (40%) 188/249 (76%) -87% (-140% to -40%) Sindh08 2 - Afyon-1 64/127 (50%) 14/91 (15%) 73% (51% to 85%) Unvaccinated animals much younger - protected by maternal immunity confounded VE 3 Denizli 55/68 (81%) 134/337 (40%) 51% (41% to 59%) 4 - Afyon-2 71/124 (57%) 69/187 (37%) 36% (18% to 49%) Few unvaccinated animals Wide confidence intervals

1. Protection from Asia-1 field strain by standard potency Asia-1 Shamir vaccine was not detected in this outbreak 2. Reasonable protection from Asia-1 field strain by Asia-1 Sindh08 [TUR 11] vaccine

Conclusions Vaccine effectiveness: Give it a go! Retrospective outbreak investigation is quick and simple Useful answers Gets you into the field Learn things that nobody reports to HQ

FMD vaccine evaluation Challenge studies in vitro matching assays Postvaccination serology Vaccine effectiveness Other 48

Key References Knight-Jones T.J.D. Vaccine effectiveness guide with VE calculator from author or EuFMD or FAO-PVM? Knight-Jones T.J.D., Bulut A.N., Gubbins S., Stark K.D., Pfeiffer D.U., Sumption K.J., Paton D.J. 2014 Retrospective evaluation of foot-and-mouth disease vaccine effectiveness in Turkey. Vaccine 32(16), 1848-1855 doi: 10.1016/j.vaccine.2014.01.071 Knight-Jones T.J.D., Edmond K., Gubbins S., Paton D.J., 2014 Veterinary and human vaccine evaluation methods. Proc R Soc B 281(1784) 20132839 doi: 10.1098/rspb.2013.2839 ------------------------------------------------------------------------------------------------------------------------------------------------------- Vaccine evaluation on large-scale dairy farms using routine prophylactic schedules for FMD Lyons, N.A., Knight-Jones, T.K.D., Bartels, C., Dulu, T.D., Stärk K.D.C., Sumption, K.J., Fine, P.E.M. EuFMD Open Session 2014 online https://eufmd.rvc.ac.uk/mod/page/view.php?id=1388 Lyons NA, Stärk KD, van Maanen C, Thomas SL, Chepkwony EC, Sangula AK, Dulu TD, Fine PEM Epidemiological analysis of an outbreak of foot-and-mouth disease (serotype SAT2) on a large dairy farm in Kenya using regular vaccination. Acta Trop. 2014 Oct 24. pii: S0001-706X(14)00302-7 doi: 10.1016/j.actatropica.2014.09.010 Lyons, N.A., Knight-Jones, T.K.D., Bartels, C., Dulu, T.D., Stärk K.D.C., Sumption, K.J., Fine, P.E.M. Vaccine evaluation on large-scale dairy farms using routine prophylactic schedules for FMD EuFMD Open Session 2014 online https://eufmd.rvc.ac.uk/mod/page/view.php?id=1388 Theo Knight-Jones Thesis Field evaluation of foot-and-mouth disease vaccination in Turkey (RVC/LSHTM) will upload to https://www.researchgate.net/profile/theodore_knight-jones/contributions

FMD vaccine evaluation What post vaccination monitoring do you do? Vaccine effectiveness Batch serology under controlled conditions Post-vaccination serology in the field Vaccine matching tests Challenge studies Evaluation of different dosing regimes Vaccine coverage Other? 50

Retrospective outbreak investigation Rely on farmer & vet recollection and records Are outbreaks non-representative cases of vaccine failure? Prospective can create own vaccine groups and see what happens Cohort, randomised trial But what if no cases? VE designs & prospective needs much more resources Money & expertise & time If free zone monitor post-vaccination serology

Any questions?

Thank you for your attention!